New Study- GlucoControl Improves Long-Term Glycaemic Control
Filed with ASX · · 2 pages · English
• University of Adelaide reveals a new global breakthrough for Faulding® GlucoControl for the management of type 2 diabetes • For the first time, a non-pharmaceutical, natural food-based product has demonstrated it can significantly reduce the dangerous blood sugar spikes after a standard meal (converting meals to be “low GI”) and improve overall glycaemic control (HbA1c) in the long term • Fauldi
EVE Health Group Limited on 6ix
Earlier from EVE Health
- Omniblend Innovation Enters into US Representation Deal
- GlucoControl Momentum
- GlucoControl Pre-Meal Drink Launched
- Extension of Omniblend Innovation Tranche 2 Settlement
- Non-Renounceable Issue
Later from EVE Health
- Placement to Chinese Pharmaceutical and Investment Group
- Omni Innovation secures UK Distribution Deal
- Omni Innovation Market Update
- Notification of Rights Issue Shortfall
- $1.6m Placement for Omni Innovation Investment
Follow EVE Health into a list and get an email when it puts out news.
Follow EVE Health